The Effect of Acute Normovolemic Hemodilution on Intraoperative Allogeneic Transfusion in Bone Tumor Surgery: a Prospective, Randomized Controlled Trial
Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
The prevention of intraoperative allogenetic blood transfusion has the potential to reduce complications, hospital stays, and long-term prognosis in patients undergoing bone tumor surgery. Data from previous studies suggest that the clinical efficacy of acute normovolemic hemodilution (ANH) has always been controversial, and intraoperative fluid administration strategy is an important confounding factor. The HEAL trial will assess whether ANH will reduce the volume of intraoperative allogeneic red blood cell transfusion when applying goal-directed fluid therapy in patients undergoing bone tumor surgery.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• age 18 to 75 years;
• undergoing elective bone tumor resection surgery;
• preoperative hemoglobin ≥11 g/dL;
Locations
Other Locations
China
The Second Affiliated Hospital of Zhejiang University anesthesiology department
RECRUITING
Hangzhou
Time Frame
Start Date: 2024-06-07
Estimated Completion Date: 2026-05
Participants
Target number of participants: 150
Treatments
Experimental: acute normovolemic hemodilution group (ANH group)
The ANH process was initiated after tracheal intubation. After completion of ANH, goal-directed fluid therapy will begin until the end of the surgery.
No_intervention: Standard Group (STD group)
After tracheal intubation, goal-directed fluid therapy will be implemented until the end of the surgery.
Related Therapeutic Areas
Sponsors
Leads: Second Affiliated Hospital, School of Medicine, Zhejiang University